Drug Trial Radar · NCT00763022
Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Nov 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
302
Actual
Start
Nov 2003
Primary completion
Dec 2004
Study completion Dec 2004
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 30, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 25 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in Type 2 Diabetes subjects.
Conditions
- Diabetes Mellitus
Interventions
TAK-559Drug
TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
TAK-559Drug
TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
PlaceboDrug
TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Baseline in Glycosylated hemoglobin.Time frame: Weeks: 4, 8, 12, 16, 20 and Final Visit.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.